Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: An integrated analysis of the complete database of multicenter placebo-controlled trials

por Asherson, Philip, Bushe, Chris, Saylor, Keith, Tanaka, Yoko, Deberdt, Walter, Upadhyaya, Himanshu
Publicado 2014

Typology of patients with fibromyalgia: cluster analysis of duloxetine study patients

por Lipkovich, Ilya A, Choy, Ernest H, Van Wambeke, Peter, Deberdt, Walter, Sagman, Doron
Publicado 2014

Schizophrenia symptoms and functioning in patients receiving long-term treatment with olanzapine long-acting injection formulation: a pooled analysis

por Peuskens, Joseph, Porsdal, Vibeke, Pecenak, Jan, Handest, Peter, D'yachkova, Yulia, Brousil, Radim, Deberdt, Walter
Publicado 2012

Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsy...

por Lipkovich, Ilya A, Deberdt, Walter, Csernansky, John G, Sabbe, Bernard, Keefe, Richard SE, Kollack-Walker, Sara
Publicado 2009

Prevalence of ADHD in nonpsychotic adult psychiatric care (ADPSYC): A multinational cross-sectional study in Europe

por Deberdt, Walter, Thome, Johannes, Lebrec, Jeremie, Kraemer, Susanne, Fregenal, Irene, Ramos-Quiroga, J. Antoni, Arif, Muhammad
Publicado 2015

Risk of Venous Thromboembolism Among Patients with Atopic Dermatitis: A Cohort Study in a US Administrative Claims Database

por Meyers, Kristin J., Silverberg, Jonathan I., Rueda, Maria Jose, Goodloe, Robert, Pierce, Evangeline J., Deberdt, Walter, Brinker, Dennis R.
Publicado 2021

Double-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaff...

por Deberdt, Walter, Lipkovich, Ilya, Heinloth, Alexandra N, Liu, Lin, Kollack-Walker, Sara, Edwards, Sara E, Hoffmann, Vicki Poole, Hardy, Thomas A
Publicado 2008

Baricitinib and the Risk of Incident Interstitial Lung Disease: A Descriptive Clinical Case Report from Clinical Trials

por Salvarani, Carlo, Sebastiani, Marco, Dieude, Philippe, Garcia, Miriam, Deberdt, Walter, Rogai, Veronica, de la Torre, Inmaculada, Inciarte-Mundo, José, Balsa, Alejandro
Publicado 2021

Correction to: A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

por Bieber, Thomas, Feist, Eugen, Irvine, Alan D., Harigai, Masayoshi, Haladyj, Ewa, Ball, Susan, Deberdt, Walter, Issa, Maher, Grond, Susanne, Taylor, Peter C.
Publicado 2023

A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19

por Bieber, Thomas, Feist, Eugen, Irvine, Alan D., Harigai, Masayoshi, Haladyj, Ewa, Ball, Susan, Deberdt, Walter, Issa, Maher, Grond, Susanne, Taylor, Peter C.
Publicado 2022

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated d...

por Taylor, Peter C, Takeuchi, Tsutomu, Burmester, Gerd R, Durez, Patrick, Smolen, Josef S, Deberdt, Walter, Issa, Maher, Terres, Jorge Ross, Bello, Natalia, Winthrop, Kevin L
Publicado 2022

Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications

por Taylor, Peter C., Bieber, Thomas, Alten, Rieke, Witte, Torsten, Galloway, James, Deberdt, Walter, Issa, Maher, Haladyj, Ewa, De La Torre, Inmaculada, Grond, Susanne, Wollenberg, Andreas
Publicado 2023

Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease R...

por Salinas, Claudia A., Louder, Anthony, Polinski, Jennifer, Zhang, Tancy C., Bower, Hannah, Phillips, Syd, Song, Yufei, Rashidi, Emaan, Bosan, Rafia, Chang, Hsiu-Ching, Foster, Nicole, Gershenson, Bernice, Yamanaka, Hisashi, Kishimoto, Mitsumasa, Tanaka, Yoshiya, Fischer, Peter, Zhu, Baojin, Faries, Douglas, Mai, Xiaodan, Doherty, Brett T., Grelaud, Angela, Thurin, Nicolas H., Askling, Johan, Deberdt, Walter
Publicado 2022

How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years

por Epelbaum, Stéphane, Paquet, Claire, Hugon, Jacques, Dumurgier, Julien, Wallon, David, Hannequin, Didier, Jonveaux, Thérèse, Besozzi, Annick, Pouponneau, Stéphane, Hommet, Caroline, Blanc, Frederic, Berly, Laetitia, Julian, Adrien, Paccalin, Marc, Pasquier, Florence, Bellet, Julie, Boutoleau-Bretonniere, Claire, Charriau, Thiphaine, Rouaud, Olivier, Madec, Olivier, Mouton, Aurélie, David, Renaud, Bekadar, Samir, Fabre, Roxane, Liegey, Emmanuelle, Deberdt, Walter, Robert, Philippe, Dubois, Bruno
Publicado 2019